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Abstract
Background: The main purpose of the present study is to evaluate whether treatment with long-acting human
glucagon-like peptide-1 liraglutide was associated with an improvement of excessive daytime sleepiness (EDS) in
obese subjects with type-2 diabetes.
Methods: This single-centre retrospective study included 158 obese (body mass index [BMI] ≥ 30 kg/m2) adult
subjects with type-2 diabetes who were initiated with liraglutide treatment at least 3 months before study
inclusion. Data of the Epworth Sleepiness Scale (ESS), anthropometric parameters, glucose-control and metabolic
parameters were collected at liraglutide initiation (baseline) and at months 1 and 3 after liraglutide initiation.
Results: Significant reductions in ESS score were achieved at months 1 (−1.3 ± 2.8, p < 0.001) and 3 (−1.5 ± 3.0, p < 0.001)
after liraglutide introduction. After 3 months of treatment with liraglutide, significant changes in body weight (p < 0.001),
BMI (p < 0.001), waist (p < 0.001) and neck circumferences (p < 0.005), HbA1c (p < 0.001), mean blood glucose (p < 0.001),
fasting plasma glucose (p < 0.001), triglycerides (p < 0.01) and total cholesterol (p < 0.001) were achieved.
Conclusions: After 3 months of treatment with liraglutide a significant reduction in EDS was observed in obese
subjects with type-2 diabetes. Besides this, significant changes in body weight and metabolic parameters of
diabetes control were also accomplished. Further investigation is required to determine whether liraglutide could
improve other abnormal sleep patterns and obstructive sleep apnoea.
Keywords: Excessive daytime sleepiness, Abnormal sleep patterns, Obstructive sleep apnoea, Type 2 diabetes,
Obesity, Liraglutide, Glucagon-like peptide-1
Background
Abnormal sleep patterns (ASPs), characterized by short
or long durations of sleep and excessive daytime sleepi-
ness (EDS), have a considerable impact on an individ-
ual’s health [1]. Obstructive sleep apnea (OSA) is the
most common form of ASP, characterized by the repeti-
tive complete or partial collapse of the upper airway
during sleep [2]. There is a growing body of literature
describing the association between ASPs and the
subsequent development of type-2 diabetes, even in non-
obese individuals [3–7]. EDS is more prevalent in subjects
with diabetes and in subjects with insulin resistance, a
well-known prediabetic condition [8, 9]. Additionally,
OSA has also been shown to impact on glycemic control
among diabetic patients, independently of obesity [10].
Recently, a study concluded that impaired sleep quality
and daytime sleepiness are associated with decreased
diabetes self-management in adults with type 2 diabetes
[11]. EDS has been also related to severe hypoglycemia
in subjects with type 2 diabetes in the Edinburgh type 2
diabetes study [12]. Quality of life and life expectancy
could be affected by this condition in this population.
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In a number of clinical studies, bariatric surgery-
induced weight loss in obese subjects was associated
with a dramatic improvement in subjective sleepiness, as
well as other associated comorbidities [13–15]. EDS was
also reduced with a weight reduction program, including
dietary counselling and behavioral change support [16].
Liraglutide, a long-acting human glucagon-like peptide-
1 receptor agonist (GLP-1ra) [17], is indicated for the
treatment of type 2 diabetes. Liraglutide exerts its potent
glucose-lowering effect through different mechanisms that
lead to clinically significant reductions in glycated haemo-
globin (HbA1c) and body weight [18]. A reduction of in-
sulin resistance has been proved in patients with type 2
diabetes treated with liraglutide [19].
Lower body weight, decreased insulin resistance and
an improvement in glycaemic control could ameliorate
the perceived quality of life of subjects with type 2 dia-
betes and, to some extent, to relieve EDS.
Therefore, all the above prompted us to evaluate
whether treatment with GLP-1ra liraglutide was associ-
ated with an improvement of EDS in obese subjects with
type-2 diabetes in routine clinical practice setting.
Methods
This retrospective observational study was carried out
at the Hospital General de Segovia (Segovia, Spain) in
accordance with the Declaration of Helsinki, including
all amendments. It was approved on February 4th 2012
by the Clinical Research and Ethics Commission of the
Hospital General de Segovia (Study code SEE-DIA-
2012-11). All participants provided written informed
consent to use their data prior to the study.
Study subjects
The study population comprised obese (BMI ≥ 30 kg/m2)
adult subjects with a documented diagnosis of type 2
diabetes who were initiated on liraglutide (Victoza®,
Novo Nordisk, Bagsvaerd, Denmark) treatment at least
3 months before study inclusion. A pre-existing clinical
diagnosis of OSA was not deemed necessary for inclu-
sion. No patient was treated with continuous positive
airway pressure (CPAP) during this study period. Sub-
jects were excluded if they had undergone bariatric sur-
gery or presented weight loss > 5 % within the previous
6 months. Patients with cognitive impairment were also
excluded.
Measurements
Following routine clinical practice, anthropometric pa-
rameters, glycaemic control and metabolic measure-
ments, and the Epworth Sleepiness Scale (ESS) score
data were retrospectively obtained from medical records
at three time points: at liraglutide initiation (baseline)
and at months 1 and 3 after liraglutide initiation.
Anthropometric parameters
Height (m) and weight (kg) were recorded. Body mass
index (BMI) was calculated as weight/height squared
(kg/m2). Waist circumference was measured at umbilical
level in standing positions with a non-stretchable tape
(cm). Also, body composition measurements were deter-
mined by bioelectrical impedance.
Glucose control measurements and metabolic parameters
Glucose control measurements included HbA1c, mean
blood glucose (MBG) from self-monitored blood glucose
profiles and fasting plasma glucose (FPG). The metabolic
parameters included the collection of high-density-
lipoprotein cholesterol (HDL), low-density-lipoprotein
cholesterol (LDL), total cholesterol (TC) and triglycer-
ides (TG) levels.
Epworth Sleepiness Scale
The ESS score was used to measure the clinical impact
of EDS. It is defined as a simple and self-administered
questionnaire which provides a measurement of the sub-
ject’s general level of sleep propensity and likelihood of
dozing off in eight different real-life situations. All items
are rated on a 4-point Likert scale, 0 = would never doze,
1 = slight chance of dozing, 2 =moderate chance of doz-
ing, 3 = high chance of dozing. Scores vary from 0 to 24,
with higher scores indicating higher levels of sleepiness
[20]. At present, there are no universally adapted cut-off
ranges for the ESS, but Drager et al. determined the sen-
sitivity and specificity of ESS in predicting OSA (defined
as ESS score >10) as 49 % and 80 %, respectively [21].
According to domain experts, we considered a 1-point
reduction in ESS score to be clinically significant [22].
Statistical considerations
The values are expressed as mean ± standard deviation
(SD) for quantitative variables and as percentages for
categorical variables. Means were compared with T-test
and the correlation analyses were assessed with the Pear-
son/Spearman correlation coefficient. The significance
level was determined at p < 0.05 and all statistical ana-
lyses were carried out with the statistical package SPSS
v.18.0 (SPSS, Inc., Chicago, IL).
Results
Subjects characteristics
Between March 2012 and June 2013, a total of 163 sub-
jects were included. Four subjects were excluded due to
screening failure (n = 2) and incomplete data (n = 2), and
another subject did not meet all the selection criteria.
Thus, the evaluable population comprised 158 subjects,
whose clinical and metabolic parameters are listed in
Table 1. At baseline, mean ESS score was 5.9 ± 4.5 and
26 (17.4 %) subjects reached an ESS > 10.
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Subjects were initiated with liraglutide treatment injected
subcutaneously from the starting dose of 0.6 mg/day and
were increased over one week to 1.2 mg/day by the attend-
ing physicians.
Changes of ESS score, anthropometric data, glucose-control
measurements and metabolic parameters
The evolution of body weight, HbA1c and ESS score
from baseline to months 1 and 3 are depicted in Fig. 1.
Pairwise comparisons showed that the ESS score sig-
nificantly decreased from baseline to month 1 (6.3 ± 4.6
vs 4.9 ± 3.9; p < 0.001) and from baseline to month 3
(5.7 ± 4.4 vs 4.2 ± 3.6; p < 0.001). After three months of
treatment with liraglutide, significant reductions were
achieved in the means of body weight (102.8 ± 17.9 kg
vs 98.4 ± 16.9 kg, p < 0.001), BMI (39.6 ± 6.8 kg/m2vs
37.9 ± 6.4 kg/m2; p < 0.001), waist circumference (122.1 ±
14.0 cm vs 118.9 ± 13.3 cm; p < 0.001) and neck circumfer-
ence (42.2 ± 3.3 cm vs 40.8 ± 3.3 cm; p < 0.005), while the
body fat percentage hardly changed (42.1 ± 7.6 % vs 41.2 ±
8.1 %; p = 0.173). Comparison of glucose-control measure-
ments and metabolic parameters between baseline and
month 3 are presented in Table 2.
The relative changes in HbA1c and body weight,
HbA1c and ESS, as well as in body weight and ESS
from baseline to month 3 after liraglutide initiation
are presented as scatter plots in Fig. 2a, b and c, re-
spectively. Overall, the majority of the study subjects
were located in the lower left quadrant, i.e. HbA1c,
body weight, and ESS score decreased for these
individuals.
Correlation of ESS score with the analytical parameters
and the anthropometric measures
Baseline ESS score was negatively correlated with base-
line body weight, BMI, waist perimeter, percentage of
body fat, and HDL levels (Table 3). However, the only
variable associated with changes in ESS score was ‘re-
ductions in body weight’ (r = 0.269, p < 0.05). The rest of
the parameters did not achieve statistical significance.
Discussion
To the best of our knowledge, this is the first study
showing an association of liraglutide-induced body
weight reduction and an improvement of EDS in obese
subjects with type 2 diabetes in routine clinical practice.
Recent scientific contributions are suggesting that ASPs,
which includes EDS, are not only related to impaired
health-related quality of life, but also influence the
microvascular complications of diabetes (i.e. diabetic
neuropathy) [23].
Within three months of therapy with liraglutide, signifi-
cant reductions were achieved not only in body weight
and BMI, but also in waist and neck circumferences.
Table 1 Baseline characteristics (N = 158)
Characteristics Value




Duration of type 2 diabetes (years), mean ± SD 11.0 ± 7.2
BMI (kg/m2), mean ± SD 38.1 ± 6.6
Waist perimeter (cm), mean ± SD 119.2 ± 13.7
Body fat (%), mean ± SD 40.6 ± 7.7
HbA1c (mmol/mol), mean ± SD 68 ± 16
MBG (mmol/L), mean ± SD 10.8 ± 2.4
FPG (mmol/L), mean ± SD 10.1 ± 3.6
HDL (mmol/L), mean ± SD 1.1 ± 0.3
LDL (mmol/L), mean ± SD 2.7 ± 1.0
TC (mmol/L), mean ± SD 4.8 ± 1.3
BMI body mass index, FPG fasting plasma glucose, HbA1c haemoglobin A1c,
HDL high-density-lipoprotein cholesterol, LDL low-density-lipoprotein choles-
terol, MBG mean blood glucose, SD standard deviation, TC total cholesterol
Fig. 1 Evolution of body weight (a), HbA1c (b) and ESS score (c)
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Concurrently, ESS score was reduced following one
month of follow-up and was maintained after three
months.
In our study, baseline anthropometric measures of
obesity were negatively correlated with baseline ESS
score. Some previous studies showed that the association
between diabetes or insulin resistance and EDS was in-
dependent of obesity [8, 9]. As an example, Dixon et al.
found that anthropometric measures explained only 3 %
of ESS score variance in 1055 subjects presenting for
obesity surgery [8]. Although our study population com-
prised a sample of very obese (mean BMI, 38.1 kg/m2)
subjects with type 2 diabetes, due to the reimbursement
policy for liraglutide prescription in Spain, it is possible
that obesity in this particular group of patients was not
determinant for baseline EDS. Despite changes in ESS
score were shown to correlate positively with the reduc-
tion in body weight, no significant relation was achieved
with the change in total body fat mass. This finding is
consistent with earlier studies showing similar reduc-
tions in ESS score with surgical or non-pharmacological
interventions reducing body weight [13–16].
Additionally to the direct effect of weight loss in EDS,
a positive impact on perceived wellbeing or mood could
be implicated in this improvement, because EDS was as-
sociated with poor energy and symptoms of depression
in previous studies [7].
Liu et al. showed that EDS diagnosed with ESS, was
prevalent amongst the insulin-resistant subgroup of
obese individuals in comparison to their weight-matched
insulin-sensitive counterpart [24]. We measured two
surrogate markers of insulin resistance: HDL-cholesterol
levels and waist circumference. Baseline ESS was corre-
lated with low HDL-cholesterol levels in our sample. Re-
garding anthropometric markers of insulin resistance,
previous studies confirmed a relationship between EDS
and greater waist circumference [25, 26]. The present
study showed that liraglutide effectively reduced waist
circumference, finally accompanied by a significant de-
crease in the mean ESS score.
In this context, an important perspective to consider is
whether sleep/wake patterns could be partly modulated
by food intake, especially with a high-fat dietary intake.
Findings from several studies conducted in animal
models demonstrated that high-fat diet and weight gain
were associated with impaired sleep patterns, with more
sleep time during the animals’ subjective day [27–29];
Wells et al. explored in a small group of adult volunteers
(n = 16) the effects of a meal on objective and subjective
measures of daytime sleepiness, showing that regular in-
gestion of fat-rich meals and significant excess of nutri-
ents can predict EDS and poor quality of nocturnal sleep
[30]. Clinical data showed reduced food intake, en-
hanced satiety and subsequent reductions in body weight
were achieved upon the administration of GLP-1ra in
patients with type 2 diabetes [31] and non-diabetic
adults [32]. Interestingly, in a small study conducted
with 20 obese and type-2 diabetic Japanese subjects,
short-term treatment with liraglutide effectively reduced
visceral fat adiposity, appetite and the urge for fat intake
[33]. Collectively, we could contemplate that GLP-1ra
liraglutide could improve EDS not only as a result of
weight reduction, but also by decreasing appetite and re-
ducing fat intake.
Our study participants were obese and had type-2
diabetes. After three months of treatment with liraglu-
tide 75 % of subjects resulted in the reduction of both
HbA1c and body weight, 17.5 % of patients revealed
weight reduction but deterioration of HbA1c, while
2.6 % of subjects presented improvement in HbA1c
levels but weight gain (Fig. 2a). These results entail that
GLP-1ra liraglutide exerts its glucose-lowering action
and improvement of body weight through different mech-
anisms. Regulatory agencies and international guidelines,
such as the National Institute for Health and Care Excel-
lence (NICE guidelines) [34] for the management of type
2 diabetes recommend to promote not only HbA1c reduc-
tion, as an indicator of metabolic improvement, but also
weight loss (even at a lesser degree) as definition of “re-
sponders” to a GLP-1ra treatment for type 2 diabetes.
Table 2 Pairwise comparison of glucose-control measurements and metabolic parameters after 3 months of treatment with
liraglutide
Baseline (mean ± SD) Month 3 (mean ± SD) p-value
HbA1c (mmol/mol) 68 ± 16 56 ± 14 <0.001
MBG (mmol/L) 10.8 ± 2.4 9.1 ± 2.0 <0.001
FPG (mmol/L) 10.7 ± 4.1 7.9 ± 2.1 <0.001
TG (mmol/L) 2.7 ± 3.7 1.7 ± 1.2 <0.01
HDL (mmol/L) 1.0 ± 0.2 0.9 ± 0.2 NS
LDL (mmol/L) 3.0 ± 1.1 2.6 ± 0.6 NS
TC (mmol/L) 5.1 ± 1.2 4.3 ± 0.7 <0.001
FPG fasting plasma glucose, HbA1c haemoglobin A1c, HDL high-density-lipoprotein cholesterol, LDL low-density-lipoprotein cholesterol, MBG mean blood glucose,
NS not significant, SD standard deviation, TC total cholesterol, TG triglycerides
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Therefore, long-acting GLP-1ra liraglutide therapy ap-
pears to be a promising new agent for the management of
ASPs in obese subjects with type 2 diabetes, especially
when weight loss is a major concern.
Some limitations of this study need to be highlighted
when interpreting the results. It should be noted that data
from sleep studies (i.e. polysomnography) are lacking. The
reason behind is that the study was aimed to reflect
merely routine clinical practice, and no interventions or
new procedures other than physicians’ daily routine were
conducted. However, in light of all the promising results
obtained, further prospective clinical studies should be
conducted addressing this clinical endpoint. It is also
worth acknowledging that the present study is an observa-
tional study, but not a randomized clinical trial. Although
conducting observational studies are of great relevance to
learn about the conditions derived from the routine clin-
ical practice setting, they do not provide strong evidence.
Furthermore, other factors in a free living environment
might impact on the results, such as diet or exercise. Fi-
nally, it can be ascertained from the lack of a comparator
group and the retrospective nature of the study design
that biases could have been introduced when collecting
data.
Conclusions
In conclusion, three months of treatment with liraglutide
effectively reduce body weight and waist circumference
and ameliorates the glycaemic control measurements
and lipid parameters. Concurrently, an improvement in
mean ESS score was also achieved. Nevertheless, further
research is needed to confirm and expand these prelim-
inary results.
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